Immunity & Infection Research Centre, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada.
Future Microbiol. 2012 Sep;7(9):1047-59. doi: 10.2217/fmb.12.85.
Leishmaniasis is one of the major neglected tropical diseases of the world. It is present in 88 countries with an estimated number of 500,000 cases of visceral leishmaniasis and 1.5 million cases of cutaneous disease. No effective vaccinations are available against leishmaniasis and the efficacy of existing treatments is compromised due to the emergence of drug resistance. Thus, there is an urgent need to develop new compounds with antileishmanial activity. Antimicrobial peptides have potential as novel antileishmanial therapy, either for use alone or in combination with current drug regimens. The modes of action of these peptides against Leishmania includes: membrane disruption leading to necrotic cell death; induction of apoptosis; binding to intracellular target(s); and indirect effects via immunomodulation of host immune cells. This article reviews the mechanisms of action of antimicrobial peptides with leishmanicidal activity.
利什曼病是世界上主要的被忽视热带病之一。它存在于 88 个国家,估计有 50 万例内脏利什曼病和 150 万例皮肤疾病。目前还没有针对利什曼病的有效疫苗,而且由于耐药性的出现,现有治疗方法的疗效受到影响。因此,迫切需要开发具有抗利什曼病活性的新化合物。抗菌肽具有作为新型抗利什曼病疗法的潜力,无论是单独使用还是与现有药物方案联合使用。这些肽对利什曼原虫的作用模式包括:破坏细胞膜导致坏死性细胞死亡;诱导细胞凋亡;与细胞内靶标结合;以及通过免疫调节宿主免疫细胞的间接作用。本文综述了具有杀利什曼原虫活性的抗菌肽的作用机制。